sysa1801,afm-24,eli-002
checkpoint therapeutics,cspc pharmaceuticals,affimed,allogene therapeutics,elicio therapeutics,elevation oncology
['sysa1801', 'afm24', 'cspc', 'lung', 'lymphoma', 'eli-002 ', '$cspcy', 'allogene therap', '$afmd', '$allo', '$ckpt', 'affimed']
$allo: allogene therapeutics presents promising lymphoma data.
$ckpt: precigen's hpv cancer therapy shows promise.
$afmd: affimed presents afm24 lung cancer data.
$eltx: positive phase 1 for eli-002 cancer treatment.
$cspcy $wst: sysa1801 clinical data presented at asco.
BioPharma/Biotech Intel.  Daily $XBI $XPH Market Movers

Database: https://t.co/IBOqbSoYuc
Clinical trial tools: https://t.co/A77u9Q84Dc  http://globalclinicalt